Free Trial

Brainsway (BWAY) Competitors

Brainsway logo
$12.11 -0.09 (-0.74%)
As of 12:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BWAY vs. INMD, MDXG, KMTS, SIBN, IRMD, CBLL, EMBC, BBNX, AVNS, and BVS

Should you be buying Brainsway stock or one of its competitors? The main competitors of Brainsway include InMode (INMD), MiMedx Group (MDXG), Kestra Medical Technologies (KMTS), SiBone (SIBN), iRadimed (IRMD), CeriBell (CBLL), Embecta (EMBC), Beta Bionics (BBNX), AVANOS MEDICAL (AVNS), and Bioventus (BVS). These companies are all part of the "medical equipment" industry.

Brainsway vs. Its Competitors

InMode (NASDAQ:INMD) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

InMode has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, Brainsway has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.

68.0% of InMode shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 6.9% of InMode shares are owned by insiders. Comparatively, 19.0% of Brainsway shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

InMode has a net margin of 44.79% compared to Brainsway's net margin of 9.01%. InMode's return on equity of 17.17% beat Brainsway's return on equity.

Company Net Margins Return on Equity Return on Assets
InMode44.79% 17.17% 15.20%
Brainsway 9.01%7.35%4.72%

InMode currently has a consensus price target of $18.54, suggesting a potential upside of 30.12%. Brainsway has a consensus price target of $14.25, suggesting a potential upside of 17.67%. Given InMode's higher probable upside, research analysts plainly believe InMode is more favorable than Brainsway.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InMode
0 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.13
Brainsway
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, InMode had 12 more articles in the media than Brainsway. MarketBeat recorded 13 mentions for InMode and 1 mentions for Brainsway. Brainsway's average media sentiment score of 1.87 beat InMode's score of 0.59 indicating that Brainsway is being referred to more favorably in the news media.

Company Overall Sentiment
InMode Positive
Brainsway Very Positive

InMode has higher revenue and earnings than Brainsway. InMode is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMode$394.82M2.28$181.27M$2.336.12
Brainsway$43.46M5.27$2.92M$0.2060.55

Summary

InMode beats Brainsway on 10 of the 16 factors compared between the two stocks.

Get Brainsway News Delivered to You Automatically

Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BWAY vs. The Competition

MetricBrainswayMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$228.84M$10.16B$5.56B$9.26B
Dividend YieldN/A2.09%4.23%4.03%
P/E Ratio60.5516.9228.5819.56
Price / Sales5.2729.21434.47183.65
Price / Cash49.0722.6736.0257.93
Price / Book3.663.588.165.58
Net Income$2.92M$233.40M$3.24B$257.82M
7 Day Performance-6.85%-3.34%-0.64%-0.39%
1 Month Performance9.49%1.11%4.93%7.80%
1 Year Performance81.29%-19.69%26.04%12.95%

Brainsway Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BWAY
Brainsway
2.6509 of 5 stars
$12.11
-0.7%
$14.25
+17.7%
+76.8%$228.84M$43.46M60.55120Positive News
INMD
InMode
4.0614 of 5 stars
$15.10
-0.4%
$18.54
+22.8%
-20.1%$958.25M$394.82M6.48480News Coverage
Positive News
MDXG
MiMedx Group
3.6738 of 5 stars
$6.48
+2.2%
$12.50
+92.9%
-11.2%$936.43M$348.88M22.64870News Coverage
Analyst Forecast
KMTS
Kestra Medical Technologies
N/A$14.75
-5.9%
$27.50
+86.4%
N/A$804.63MN/A0.00300News Coverage
SIBN
SiBone
3.9739 of 5 stars
$18.01
-2.5%
$22.50
+24.9%
+8.6%$787.09M$167.18M-28.14350Positive News
IRMD
iRadimed
4.7046 of 5 stars
$59.02
-4.5%
$72.00
+22.0%
+25.8%$785.79M$73.24M38.08110
CBLL
CeriBell
2.6065 of 5 stars
$17.20
-9.1%
$32.14
+86.9%
N/A$684.19M$65.44M0.00N/A
EMBC
Embecta
4.7497 of 5 stars
$10.03
-2.8%
$19.33
+92.8%
-25.4%$603.13M$1.12B4.062,100News Coverage
Positive News
Analyst Forecast
BBNX
Beta Bionics
N/A$13.40
-0.9%
$23.44
+75.0%
N/A$586.18M$65.12M0.00294
AVNS
AVANOS MEDICAL
2.8697 of 5 stars
$11.87
-3.9%
N/A-44.8%$571.11M$687.80M-1.422,227News Coverage
BVS
Bioventus
2.7115 of 5 stars
$6.82
-2.8%
$13.75
+101.6%
-4.3%$560.22M$567.70M-11.181,200

Related Companies and Tools


This page (NASDAQ:BWAY) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners